When tumor suppressor TGFβ meets the HER2 (ERBB2) oncogene

Journal of Mammary Gland Biology and Neoplasia

Volumn 16, Issue 2, 2011, Pages 81-88

  Chow, Amy ^a   Arteaga, Carlos L ^b   Wang, Shizhen Emily ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Breast cancer; Drug resistance; HER2 (ERBB2); TGF

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; INTEGRIN; SMAD PROTEIN; TRANSFORMING GROWTH FACTOR BETA;

BREAST CANCER; BREAST EPITHELIUM; CANCER CELL; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER INHIBITION; CANCER INVASION; CANCER RESISTANCE; CANCER SURVIVAL; CARCINOGENESIS; CELL PROLIFERATION; EPITHELIUM CELL; GENE AMPLIFICATION; GENE CLUSTER; GENE FUNCTION; GENE OVEREXPRESSION; GENE SILENCING; GENETIC TRANSCRIPTION; HUMAN; IN VITRO STUDY; METASTASIS; MITOGENESIS; MOLECULARLY TARGETED THERAPY; NONHUMAN; ONCOGENE; PROTEIN PROTEIN INTERACTION; REVIEW; SIGNAL TRANSDUCTION; SURVIVAL TIME;

ANIMALS; BREAST NEOPLASMS; FEMALE; GENES, ERBB-2; HUMANS; RECEPTOR, ERBB-2; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA;

EID: 79959510568     PISSN: 10833021     EISSN: 15737039     Source Type: Journal    
DOI: 10.1007/s10911-011-9206-4     Document Type: Review

References (50)

1. J Massague SW Blain RS Lo 2000 TGFbeta signaling in growth control, cancer, and heritable disorders Cell 103 2 295 309 11057902 10.1016/S0092- 8674(00)00121-5 1:CAS:528:DC%2BD3cXns1Clt7w%3D
2. KB Ewan G Shyamala SA Ravani, et al. 2002 Latent transforming growth factor-beta activation in mammary gland: regulation by ovarian hormones affects ductal and alveolar proliferation Am J Pathol 160 6 2081 93 12057913 10.1016/S0002-9440(10)61158-3 1:CAS:528:DC%2BD38XltFOrs7g%3D (Pubitemid 34663401)
3. R Derynck YE Zhang 2003 Smad-dependent and Smad-independent pathways in TGF-beta family signalling Nature 425 6958 577 84 14534577 10.1038/nature02006 1:CAS:528:DC%2BD3sXnvV2hs7c%3D (Pubitemid 37280136)
4. R Derynck RJ Akhurst A Balmain 2001 TGF-beta signaling in tumor suppression and cancer progression Nat Genet 29 2 117 29 11586292 10.1038/ng1001-117 1:CAS:528:DC%2BD3MXnsFKgt7c%3D (Pubitemid 32952643)
5. N Dumont CL Arteaga 2003 Targeting the TGF beta signaling network in human neoplasia Cancer Cell 3 6 531 6 12842082 10.1016/S1535-6108(03)00135-1 1:CAS:528:DC%2BD3sXltlSms7c%3D (Pubitemid 36808648)
6. DJ Slamon W Godolphin LA Jones, et al. 1989 Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer Science 244 4905 707 12 2470152 10.1126/science.2470152 1:STN:280:DyaL1M3kt1Wntg%3D%3D (Pubitemid 19147683)
7. JS Ross JA Fletcher 1998 The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy Oncologist 3 4 237 52 10388110
8. Y Yarden MX Sliwkowski 2001 Untangling the ErbB signalling network Nat Rev Mol Cell Biol 2 2 127 37 11252954 10.1038/35052073 1:CAS:528: DC%2BD3MXivVWnt7k%3D (Pubitemid 33674041)
9. R Pinkas-Kramarski L Soussan H Waterman, et al. 1996 Diversification of neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions Embo J 15 10 2452 67 8665853 1:CAS:528:DyaK28XjsVGjurY%3D (Pubitemid 26151185)
10. D Graus-Porta RR Beerli JM Daly, et al. 1997 ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling Embo J 16 7 1647 55 9130710 10.1093/emboj/16.7.1647 1:CAS:528:DyaK2sXislKltLo%3D (Pubitemid 27151960)
11. LM Wang A Kuo M Alimandi, et al. 1998 ErbB2 expression increases the spectrum and potency of ligand-mediated signal transduction through ErbB4 Proc Natl Acad Sci USA 95 12 6809 14 9618494 10.1073/pnas.95.12.6809 1:CAS:528:DyaK1cXjslynuro%3D (Pubitemid 28278062)
12. R Worthylake LK Opresko HS Wiley 1999 ErbB-2 amplification inhibits down-regulation and induces constitutive activation of both ErbB-2 and epidermal growth factor receptors J Biol Chem 274 13 8865 74 10085130 10.1074/jbc.274.13.8865 1:CAS:528:DyaK1MXitFyrtLk%3D (Pubitemid 29164687)
13. AD Thor S Liu S Edgerton, et al. 2000 Activation (tyrosine phosphorylation) of ErbB-2 (HER-2/neu): a study of incidence and correlation with outcome in breast cancer J Clin Oncol 18 18 3230 9 10986055 1:CAS:528:DC%2BD3cXntFOgu7k%3D
14. M Alimandi A Romano MC Curia, et al. 1995 Cooperative signaling of ErbB3 and ErbB2 in neoplastic transformation and human mammary carcinomas Oncogene 10 9 1813 21 7538656 1:CAS:528:DyaK2MXls1artb8%3D
15. JH Pierce P Arnstein E DiMarco, et al. 1991 Oncogenic potential of erbB-2 in human mammary epithelial cells Oncogene 6 7 1189 94 1713661 1:CAS:528:DyaK3MXlsFKisbo%3D (Pubitemid 21924207)
16. SK Muthuswamy D Li S Lelievre, et al. 2001 ErbB2, but not ErbB1, reinitiates proliferation and induces luminal repopulation in epithelial acini Nat Cell Biol 3 9 785 92 11533657 10.1038/ncb0901-785 1:CAS:528: DC%2BD3MXmvF2lsrY%3D (Pubitemid 32842683)
17. P Carter L Presta CM Gorman, et al. 1992 Humanization of an anti-p185HER2 antibody for human cancer therapy Proc Natl Acad Sci USA 89 10 4285 9 1350088 10.1073/pnas.89.10.4285 1:CAS:528:DyaK3sXitFSqtb0%3D
18. R Roskoski Jr 2004 The ErbB/HER receptor protein-tyrosine kinases and cancer Biochem Biophys Res Commun 319 1 1 11 15158434 10.1016/j.bbrc.2004.04.150 1:CAS:528:DC%2BD2cXkt1Cgtbg%3D (Pubitemid 38670153)
19. J Baselga D Tripathy J Mendelsohn, et al. 1999 Phase II study of weekly intravenous trastuzumab (Herceptin) in patients with HER2/neu-overexpressing metastatic breast cancer Semin Oncol 26 4 Suppl 12 78 83 10482197 1:CAS:528:DyaK1MXmt1Sitr4%3D (Pubitemid 29411436)
20. MA Cobleigh CL Vogel D Tripathy, et al. 1999 Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease J Clin Oncol 17 9 2639 48 10561337 1:CAS:528:DyaK1MXmtlWrurk%3D (Pubitemid 29415219)
21. CL Vogel MA Cobleigh D Tripathy, et al. 2002 Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer J Clin Oncol 20 3 719 26 11821453 10.1200/JCO.20.3.719 1:CAS:528:DC%2BD38XhsVGmt7o%3D (Pubitemid 34111379)
22. Y Lu X Zi Y Zhao, et al. 2001 Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin) J Natl Cancer Inst 93 24 1852 7 11752009 10.1093/jnci/93.24.1852 1:CAS:528:DC%2BD38XltVWluw%3D%3D (Pubitemid 34048651)
23. AB Motoyama NE Hynes HA Lane 2002 The efficacy of ErbB receptor-targeted anticancer therapeutics is influenced by the availability of epidermal growth factor-related peptides Cancer Res 62 11 3151 8 12036928 1:CAS:528: DC%2BD38XksVyqs70%3D (Pubitemid 34602408)
24. FM Yakes W Chinratanalab CA Ritter, et al. 2002 Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt Is required for antibody-mediated effects on p27, cyclin D1, and antitumor action Cancer Res 62 14 4132 41 12124352 1:CAS:528:DC%2BD38XlsV2ltr0%3D (Pubitemid 34791085)
25. Y Nagata KH Lan X Zhou, et al. 2004 PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients Cancer Cell 6 2 117 27 15324695 10.1016/j.ccr.2004.06.022 1:CAS:528:DC%2BD2cXns1arsr8%3D (Pubitemid 39485684)
26. Garrett JT, Arteaga CL. Resistance to HER2-directed antibodies and tyrosine kinase inhibitors: Mechanisms and clinical implications. Cancer Biol Ther 2011;11(9).
27. RS Muraoka-Cook I Shin JY Yi, et al. 2006 Activated type I TGFbeta receptor kinase enhances the survival of mammary epithelial cells and accelerates tumor progression Oncogene 25 24 3408 23 16186809 10.1038/sj.onc.1208964 1:CAS:528:DC%2BD28XlsVersrc%3D (Pubitemid 43877044)
28. PM Siegel W Shu RD Cardiff, et al. 2003 Transforming growth factor beta signaling impairs neu-induced mammary tumorigenesis while promoting pulmonary metastasis Proc Natl Acad Sci USA 100 14 8430 5 12808151 10.1073/pnas.0932636100 1:CAS:528:DC%2BD3sXlsFGntLc%3D (Pubitemid 36842562)
29. RS Muraoka Y Koh LR Roebuck, et al. 2003 Increased malignancy of neu-induced mammary tumors overexpressing active transforming growth factor beta1 Mol Cell Biol 23 23 8691 703 14612410 10.1128/MCB.23.23.8691-8703.2003 1:CAS:528:DC%2BD3sXptFaisbk%3D (Pubitemid 37433371)
30. RS Muraoka-Cook N Dumont CL Arteaga 2005 Dual role of transforming growth factor beta in mammary tumorigenesis and metastatic progression Clin Cancer Res 11 2 Pt 2 937s 43 15701890 1:CAS:528:DC%2BD2MXislWnsrY%3D
31. A Bandyopadhyay F Lopez-Casillas SN Malik, et al. 2002 Antitumor activity of a recombinant soluble betaglycan in human breast cancer xenograft Cancer Res 62 16 4690 5 12183427 1:CAS:528:DC%2BD38XmsVShsLk%3D
32. SE Seton-Rogers Y Lu LM Hines, et al. 2004 Cooperation of the ErbB2 receptor and transforming growth factor beta in induction of migration and invasion in mammary epithelial cells Proc Natl Acad Sci USA 101 5 1257 62 14739340 10.1073/pnas.0308090100 1:CAS:528:DC%2BD2cXhtlWjtL4%3D (Pubitemid 38182676)
33. Y Ueda S Wang N Dumont, et al. 2004 Overexpression of HER2 (erbB2) in human breast epithelial cells unmasks transforming growth factor beta-induced cell motility J Biol Chem 279 23 24505 13 15044465 10.1074/jbc.M400081200 1:CAS:528:DC%2BD2cXksV2itLg%3D (Pubitemid 38725316)
34. W Xie JC Mertens DJ Reiss, et al. 2002 Alterations of Smad signaling in human breast carcinoma are associated with poor outcome: a tissue microarray study Cancer Res 62 2 497 505 11809701 1:CAS:528:DC%2BD38XhtVyht7g%3D (Pubitemid 34106424)
35. SE Wang A Narasanna CW Whitell, et al. 2007 Convergence of p53 and transforming growth factor beta (TGFbeta) signaling on activating expression of the tumor suppressor gene maspin in mammary epithelial cells J Biol Chem 282 8 5661 9 17204482 10.1074/jbc.M608499200 1:CAS:528:DC%2BD2sXhvVait7c%3D (Pubitemid 47093781)
36. M Cordenonsi S Dupont S Maretto, et al. 2003 Links between tumor suppressors: p53 is required for TGF-beta gene responses by cooperating with Smads Cell 113 3 301 14 12732139 10.1016/S0092-8674(03)00308-8 1:CAS:528:DC%2BD3sXjslOltbc%3D (Pubitemid 36556113)
37. Y Yu Y Wang X Ren, et al. 2010 Context-dependent bidirectional regulation of the mutS homolog 2 by transforming growth factor beta contributes to chemoresistance in breast cancer cells Mol Cancer Res 8 12 1633 42 21047769 10.1158/1541-7786.MCR-10-0362 1:CAS:528:DC%2BC3cXhsFOjsb3E
38. L Zheng JQ Ren H Li, et al. 2004 Downregulation of wild-type p53 protein by HER-2/neu mediated PI3K pathway activation in human breast cancer cells: its effect on cell proliferation and implication for therapy Cell Res 14 6 497 506 15625017 10.1038/sj.cr.7290253 1:CAS:528:DC%2BD2MXhtFals7g%3D (Pubitemid 43231795)
39. LT Vassilev BT Vu B Graves, et al. 2004 In vivo activation of the p53 pathway by small-molecule antagonists of MDM2 Science 303 5659 844 8 14704432 10.1126/science.1092472 1:CAS:528:DC%2BD2cXovVKmtA%3D%3D (Pubitemid 38174664)
40. A Arnal-Estape M Tarragona M Morales, et al. 2010 HER2 silences tumor suppression in breast cancer cells by switching expression of C/EBPss isoforms Cancer Res 70 23 9927 36 21098707 10.1158/0008-5472.CAN-10-0869 1:CAS:528:DC%2BC3cXhsFamurjE
41. RR Gomis C Alarcon C Nadal, et al. 2006 C/EBPbeta at the core of the TGFbeta cytostatic response and its evasion in metastatic breast cancer cells Cancer Cell 10 3 203 14 16959612 10.1016/j.ccr.2006.07.019 1:CAS:528: DC%2BD28XhtVSlu73I (Pubitemid 44311064)
42. SC Dowdy A Mariani R Janknecht 2003 HER2/neu- and TAK1-mediated up-regulation of the transforming growth factor beta inhibitor Smad7 via the ETS protein ER81 J Biol Chem 278 45 44377 84 12947087 10.1074/jbc.M307202200 1:CAS:528:DC%2BD3sXoslWmtbk%3D (Pubitemid 37377186)
43. SE Wang I Shin FY Wu, et al. 2006 HER2/neu (ErbB2) Signaling to Rac1-Pak1 Is Temporally and Spatially Modulated by Transforming Growth Factor {beta} Cancer Res 66 19 9591 600 17018616 10.1158/0008-5472.CAN-06-2071 1:CAS:528:DC%2BD28XhtVams7%2FM (Pubitemid 44623658)
44. SE Wang B Xiang R Zent, et al. 2009 Transforming growth factor beta induces clustering of HER2 and integrins by activating Src-focal adhesion kinase and receptor association to the cytoskeleton Cancer Res 69 2 475 82 19147560 10.1158/0008-5472.CAN-08-2649 1:CAS:528:DC%2BD1MXltFSisA%3D%3D
45. SE Wang B Xiang M Guix, et al. 2008 Transforming growth factor beta engages TACE and ErbB3 to activate phosphatidylinositol-3 kinase/Akt in ErbB2-overexpressing breast cancer and desensitizes cells to trastuzumab Mol Cell Biol 28 18 5605 20 18625725 10.1128/MCB.00787-08 1:CAS:528: DC%2BD1cXhtFCqsbrE
46. JJ Northey J Chmielecki E Ngan, et al. 2008 Signaling through ShcA is required for transforming growth factor beta- and neu/ErbB-2-induced breast cancer cell motility and invasion Mol Cell Biol 28 10 3162 76 18332126 10.1128/MCB.01734-07 1:CAS:528:DC%2BD1cXlvFeru78%3D (Pubitemid 351657082)
47. SE Wang Y Yu TL Criswell, et al. 2010 Oncogenic mutations regulate tumor microenvironment through induction of growth factors and angiogenic mediators Oncogene 29 23 3335 48 20383197 10.1038/onc.2010.112 1:CAS:528: DC%2BC3cXksFalt70%3D
48. MJ van de Vijver YD He LJ van't Veer, et al. 2002 A gene-expression signature as a predictor of survival in breast cancer N Engl J Med 347 25 1999 2009 12490681 10.1056/NEJMoa021967 (Pubitemid 35461656)
49. HY Chang DS Nuyten JB Sneddon, et al. 2005 Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival Proc Natl Acad Sci U S A 102 10 3738 43 15701700 10.1073/pnas.0409462102 1:CAS:528:DC%2BD2MXisVOgtr4%3D (Pubitemid 40354681)
50. LN Harris F You SJ Schnitt, et al. 2007 Predictors of resistance to preoperative trastuzumab and vinorelbine for HER2-positive early breast cancer Clin Cancer Res 13 4 1198 207 17317830 10.1158/1078-0432.CCR-06-1304 1:CAS:528:DC%2BD2sXhvF2hsbo%3D (Pubitemid 46424061)